Catalyst
Slingshot members are tracking this event:
Catalyst Pharmaceuticals Completes NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CPRX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 17, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Firdapse, Lambert-eaton Myasthenic Syndrome, Congenital Myasthenic Syndromes, Cms, Lems, Breakthrough Therapy, Orphan Drug
